SynthesisPediatric research2026
Cord blood biomarkers in infants with neonatal encephalopathy: a systematic review and meta-analysis.
Synthesis in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceCord blood biomarkers could aid in the early diagnosis of neonatal encephalopathy (NE) and detect neonates likely to benefit from interventions.
methodsA systematic review and meta-analysis were conducted. PubMed, Scopus, OVID MEDLINE, Embase, and Cochrane were searched through July 2024. Eligible studies were prospective, retrospective, longitudinal, or cross-sectional in English. Reviews, case series, case-control, and opinion articles were excluded. Standardized mean differences were calculated with random-effects models; heterogeneity was assessed with I² and bias with Egger's test.
resultsOf 1705 studies screened, 63 were reviewed and 49 meta-analyzed, covering 51 cord blood biomarkers, metabolomic profiles, and microRNA/mRNA expression profiles. Several biomarkers were significantly elevated in neonates with NE compared to controls, including tumor necrosis factor-alpha (3.34; 95%CI 2.52-4.15), prooxidant-antioxidant balance (0.80; 95%CI 0.59-1.00), activin-A (0.88; 95%CI 0.52-1.24), troponin (6.13; 95%CI 3.33-8.93), S100 calcium-binding protein B (2.74; 95%CI 0.94-4.54), glial fibrillary acidic protein, neuron-specific enolase, tau, neurofilament light protein, interleukin-6, interleukin-1, malondialdehyde, hypoxanthine, and nucleated red blood cells. Metabolomic changes and altered miRNA expression were also reported.
conclusionsEarly detection of specific cord blood biomarkers shows promise for NE diagnosis. Further prospective studies are needed to validate biomarker panels for clinical use. IMPACT: Early detection of specific cord blood biomarkers may help identifying neonates with neonatal encephalopathy (NE). Tumor necrosis factor-alpha (TNF-α), prooxidant-antioxidant balance, nucleated red blood cells, and activin-A were significantly elevated in neonates with NE compared to controls. S100 calcium-binding protein B (S100B) and IL-6 were higher in neonates with moderate/severe NE compared to neonates with mild NE. TNF-α, prooxidant-antioxidant balance, nucleated red blood cells, activin-A, S100B, and IL-6 are the most promising cord blood biomarkers for early diagnosis and disease severity assessment of NE.
Identifiers
42350770What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.